Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
88
resultados
Última actualización
02/11/2025 [07:09:00]
Resumen de: WO2025224268A1
The present invention relates to a live attenuated Gram-negative bacterium modified to enable enhanced vacuole escape. In particular, the invention relates to a live attenuated Gram-negative bacterium comprising a heterologous polynucleotide encoding a prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein said heterologous polynucleotide encoding the prokaryotic disulfide bond isomerase is operably linked to a promoter, or a live attenuated Gram-negative bacterium comprising an endogenous prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein the endogenous prokaryotic disulfide bond isomerase is upregulated compared to its basal level expression.
Resumen de: WO2025224621A1
Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.
Resumen de: WO2025224251A1
The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.
Resumen de: AU2024264505A1
Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.
Resumen de: US2025334572A1
Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.
Resumen de: WO2025225874A1
The present invention relates to a method for detecting live foodborne pathogens using novel bacteriophages LEC1, LBC9, and LSE2. By using this method, Escherichia coli, Bacillus cereus, and Salmonella spp., which are live foodborne pathogens in food, can be rapidly and accurately detected at the same time, and thus the method can be effectively used for preventing food poisoning.
Resumen de: EP4641200A2
Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.
Resumen de: WO2024137831A2
A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.
Resumen de: CN120842432A
本发明涉及一种应对多种致病性肠杆菌感染防治的融合蛋白、免疫原性组合物、重组简并疫苗，以及分子架构设计和应用等。本发明筛选到3种细胞免疫抗原Tuf、DnaK、fusA，构建的3种抗原的融合蛋白分子可显著抑制多种肠杆菌感染引起的组织病变，具有良好的免疫原性，起到有效防治和免疫保护作用，广谱且高效地预防多种致病性肠杆菌感染，具有广阔的工业应用前景。
Resumen de: WO2024192346A1
Technologies for providing immunogenic compositions (e.g., vaccines) and methods of inducing immune responses in subjects in need thereof.
Resumen de: US2025321205A1
Methods and devices are disclosed for rapid, multiplex molecular detection of diverse nucleic acid target molecules. The invention features an electrophoretic array with immobilized hydrogel microgel deposits. Each deposit comprises a three-dimensional, cross-linked polymer matrix containing an immobilized affinity-binding molecule and a porogen-derived pore network. This structure is configured for rapid molecular transport of nucleic acids (e.g., up to 800 bp), providing a localized environment for target capture, ligation of linear Rolling Circle Amplification (RCA) probes, and RCA. Target-specific components are anchored within distinct microgels for multiplexing. Electric fields enhance transport, reaction kinetics, and amplicon concentration. Detection is achieved in under 20 minutes. The specifically structured and fabricated microgels improve detection speed, sensitivity, and applicability to multiple different targets.
Resumen de: US2025321227A1
The present invention relates to diagnostic platform. More specifically, the invention relates to a dual platform composed of a detection and quantification unit and a characterization unit, systems, kits, methods and uses thereof in detection, quantification and characterization of pathogens, the system comprising monoclonal-antibody-based biosensor chips, for detection and/or quantification of pathogens in a sample, and substrate-based biosensor chips for enzymatically profiling the pathogen in the sample.
Resumen de: CN120757621A
本发明公开了一种提高重组蛋白热稳定性和溶解度的双功能蛋白标签及基于其的产品和应用，属于蛋白工程技术领域。该双功能标签的氨基酸序列SEQ ID NO:1所示，具有70%‑95%以上的相似度，其氨基酸序列变异主要存在但不限于二级结构位置。该双功能标签可在目的蛋白的N端或C端使用，适用于原核表达系统中融合蛋白的表达和纯化。本发明通过理性设计改造天然蛋白的疏水性区域，解决了现有蛋白标签分子量大、易遮蔽目标蛋白活性结构域、标签切除后残留非天然氨基酸可能破坏蛋白正确折叠等技术问题，显著提升融合蛋白在大肠杆菌表达系统中的可溶性及热稳定性，适用于包涵体蛋白的功能性表达与工业化应用。
Resumen de: JP2025149945A
【課題】 本発明が解決しようとする課題は、サルモネラの検出を、血清型横断的かつ他の菌種とは特異的に行うことである。【解決手段】サルモネラの加熱死菌体とアジュバントを含む抗原液を、ＢＡＬＢ／ｃマウスに接種した。接種後、マウスの脾細胞またはリンパ節細胞とＰ３Ｕ１とを融合させてハイブリドーマを作製し、その中から、サルモネラ特異性を示すモノクローナルＩｇＧ抗体を産生するハイブリドーマを選抜し、優れたサルモネラ特異性抗体を産生する３つのハイブリドーマを取得することに成功した。次いで、これらのモノクローナル抗体を用いて、サンドイッチＥＬＩＳＡにより複数血清型のサルモネラおよび他の菌種の検出を行ったところ、血清型横断的にサルモネラを検出し、他の菌種を検出しないという結果を得た。【選択図】図１
Resumen de: CN120737217A
本发明提供了一种亚单位疫苗及其制备方法与应用。所述疫苗包括式（1）的融合蛋白，D0a‑D1a‑Linker‑HA‑Linker‑D1b‑D0b（1）其中，D0a和D0b分别为细菌鞭毛蛋白FliC的D0结构域或其功能性片段的N端部分和C端部分，D0a和D0b组成细菌鞭毛蛋白FliC的D0结构域或其功能性片段；D1a和D1b分别为细菌鞭毛蛋白FliC的D1结构域或其功能性片段的N端部分和C端部分，D1a和D1b组成细菌鞭毛蛋白FliC的D1结构域或其功能性片段；HA为流感病毒HA蛋白的抗原表位或其功能性片段，linker为连接子，‑为肽键或其他化学键。可以用于流感病毒的净化工作，安全有效，具有较高的应用价值。
Resumen de: WO2025202803A1
The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.
Resumen de: US2025304662A1
Among the various aspects of the present disclosure is the provision of FimH inhibiting compositions and methods of use thereof. FimH inhibiting compositions that target and inhibit FimH, including monoclonal antibodies, are described. Methods of identifying FimH inhibiting antibodies are also described. Further, a method of treating bacterial infections, including urinary tract infections, is described.
Resumen de: EP4623922A2
The invention relates to guided nucleases, CRISPR/Cas systems, crRNAs, single gRNAs, vectors, methods and pharmaceutical compositions, for example for targeting sporulating bacteria, or for targeting C difficile, Salmonella, E coli or Streptococcus.
Resumen de: CN120718821A
本发明公开了一种基因工程菌及其在抗革兰氏阴性菌感染中的应用。所述基因工程菌为在出发菌株中利用细菌表面展示系统过表达菌毛黏附素、肠道消化酶识别位点和细菌素。本发明的基因工程菌能在肠道中肠激酶的作用下，释放有活性的细菌素并暴露出菌毛黏附素，并实现杀灭肠道内的鼠伤寒沙门氏菌，及预防鼠伤寒沙门氏菌的再次定植的效果。
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: US2025295770A1
A composition and method for therapeutic or prophylactic treatment of birds includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum.
Resumen de: WO2025199081A1
The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and/or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.
Resumen de: WO2025199547A1
A composition and method for therapeutic or prophylactic treatment of birds includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum.
Resumen de: US2025295747A1
The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and/or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.
Nº publicación: EP4621058A1 24/09/2025
Solicitante:
CNCURE CO LTD [KR]
CNCure Co., Ltd
Resumen de: EP4621058A1
The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuated Salmonella strain according to the present disclosure is designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response, whereby tumor sizes in metastatic cancers as well as primary cancers can be significantly inhibited. Thus, the strain can be advantageously used in a prophylactic or therapeutic composition for improving survival rates.
BOPI
Sede Electrónica
